Loading...
Loading...

Go to the content (press return)

Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients

Author
Molto, J.; Santos, J.; Perez, N.; Cedeño, S.; Miranda, C.; Khoo, S.; Else, L.; Llibre, J.M.; Valle, M.; Clotet, B.
Type of activity
Journal article
Journal
Antimicrobial agents and chemotherapy
Date of publication
2008-11
Volume
52
Number
11
First page
3928
Last page
3932
DOI
https://doi.org/10.1128/AAC.00520-08 Open in new window
URL
https://www.ncbi.nlm.nih.gov/pubmed/18725446 Open in new window
Abstract
The aim of this study was to evaluate the relationship between the virological response to darunavir-based salvage antiretroviral therapy and the darunavir genotypic and virtual inhibitory quotients (gIQ and vIQ, respectively). Thirty-seven HIV-infected patients failing protease inhibitor-based antiretroviral regimens who started salvage therapy containing darunavir-ritonavir were prospectively studied. The primary outcome of the study was a viral load (VL) of <50 copies/ml at week 48. The troug...
Group of research
GRBIO - Biostatistics and Bioinformatics Research Group

Participants

  • Molto Marhuenda, Jose  (author)
  • Santos, Jr  (author)
  • Perez Alvarez, Nuria  (author)
  • Cedeño, S  (author)
  • Miranda, C  (author)
  • Khoo, S  (author)
  • Else, L  (author)
  • Llibre, Josep M.  (author)
  • Valle, M  (author)
  • Clotet Sala, Bonaventura  (author)